Abstract
Cancer immunotherapeutic approaches that rely on endogenous T cell responses have shown limited success in children, a pattern attributed to the low mutational burden of pediatric tumors. Here, we report that CD8 T cells isolated from a diverse set of pediatric solid tumors are enriched for an antigen-experienced phenotype. The limited ability of immune checkpoint blockade therapy (ICBT) to trigger anti-tumor responses in children, despite the presence of activated CD8 T cells, prompted us to explore alternative underlying mechanisms restricting anti-tumor responses. Using a novel mouse tumor model that expresses a well-characterized epitope coupled to an mCherry marker, we identified antigen cross-presentation by tumor infiltrating myeloid cells as a key regulator of CD8 T cell effector function in tumors. Strikingly, age-related changes in the TME resulted in a skewing of the CD8 T cell effector fate toward a terminally differentiated state in young tumor-bearing mice. Profiling of tumor infiltrating antigen presenting cells by scRNAseq revealed a proinflammatory M1 macrophage polarization in young tumors but a predominant M2 “wound healing” response in adult tumors. Consistent with our mouse findings, analysis of immune infiltrates from human pediatric solid tumors revealed a strong correlation between the expression of PDL1 on myeloid cells and enrichment of tumor-associated CD8 T cells with an exhaustion phenotype. Collectively, these data indicate that the “young” microenvironment of an actively developing tissue/individual contributes to the generation of an immune response skewed towards a terminally differentiated state with limited plasticity, thus narrowing the window for immunotherapeutic interventions.